Clinical trials: Early-Onset Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM)
Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes
The incidence of early-onset type 2 diabetes (T2D) is increasing globally. People with early-onset T2D have faster beta-cell deterioration and more aggressive diabetes progression than their late-onset counterparts.
- Trial name
- NCT06913881
- Testing
- GLP-1
- Where
- Sweden
- Volunteers
- 92,100 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Adult-Onset, Diabetes Complications
Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients
Pancreatic Cancer is a leading cause of cancer-related death. To date, only one fifth of patients at diagnosis is presented resectable because the diagnosis is often delayed making the 5-year survival of this disease globally…
- Conditions
- Diabetes Mellitus, Adult-Onset, Diabetes Complications, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasm
- Trial name
- PaCANOD (NCT02456051)
- Where
- Italy
- Volunteers
- 21 people
- Sponsor
- University of Roma La Sapienza
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Diabetes, Autoimmune, Diabetes Mellitus, Adult-Onset
Early Insulin Treatment in Patients With Latent Autoimmune Diabetes
Among adult patients diagnosed with type 2 diabetes, about 6% have autoantibodies directed against the insulin producing beta cells in the pancreas.
- Trial name
- NCT01109927
- Testing
- Insulin
- Volunteers
- 42 people
- Sponsor
- Lund University Hospital
Type I Diabetes
Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus
This study will examine the safety of three times weekly SC injections of OPT101 at each of three dose levels over two weeks as well as one year of treatment with SC OPT101 or placebo to match at a single dose level.
- Trial name
- NCT06964087
- Testing
- OPT101
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Op-T LLC
Type 2 Diabetes Mellitus
Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients
Bariatric surgery is efficient in both inducing adequate weight loss and the control of glycemia in obese patients affected by Type 2 Diabetes Mellitus (T2DM).
- Trial name
- ESINODOP (NCT02488733)
- Testing
- LSG, CMT
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliera Santa Maria, Terni, Italy
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Early-Onset Type 2 Diabetes
Precision Diabetes Management: Integrated East-West Approach
This project will leverage a large-scale cohort of early-onset type 2 diabetes patients to conduct innovative prospective clinical research.
- Trial name
- NCT07307040
- Testing
- No interventions
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
ALS, Amyotrophic Lateral Sclerosis
NYSCF Scientific Discovery Biobank
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood cells) to make stem cells and other types of cells…
- Conditions
- ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset
- Trial name
- NCT06203106
- Testing
- Biological Sample Collection
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- New York Stem Cell Foundation Research Institute
Type 2 Diabetes Mellitus (T2DM), Beta Cell Function
Function of Beta Cells in Early-onset Diabetes Mellitus
Research objectives: Evaluate and compare the clinical and paraclinical characteristics, complications, as well as the changes in beta cell function and HbA1C levels between two patient groups over a one-year follow-up period.
- Trial name
- NCT07574138
- Testing
- Monitor and observe the clinical progression and beta cell function
- Where
- Vietnam
- Volunteers
- 296 people
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic…
- Conditions
- Type 2 Diabetes Mellitus, Impaired Glucose Tolerance, Non-Alcoholic Fatty Liver Disease, Obesity, Childhood
- Trial name
- NCT05067621
- Testing
- Semaglutide Pen Injector
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Diabetes
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an contributes to the development of many of its…
- Trial name
- NCT01107717
- Testing
- metformin\pioglitazone\exenatide, metformin, glyburide and glargine
- Where
- United States
- Volunteers
- 318 people
- Sponsor
- The University of Texas Health Science Center at San Antonio